Why the study?
The optimal pharmacologic thromboprophylaxis agent after total hip and total knee arthroplasty is uncertain, and consensus is lacking regarding comparative effectiveness and safety.
Do DOACs reduce 30-day postdischarge VTE compared to aspirin in patients undergoing total hip or knee arthroplasty?
Population
29 264 US patients undergoing total hip or total knee arthroplasty
Comparison
DOAC vs aspirin (or apixaban, rivaroxaban, enoxaparin, or warfarin)
Design
Retrospective cohort study with propensity-matched analysis
Follow-up
30 days
Authors
Loading...
Retrospective data should not change thromboprophylaxis practice; leaves open optimal agent selection after arthroplasty.
Do DOACs reduce 30-day postdischarge VTE compared to aspirin in patients undergoing total hip or knee arthroplasty?
In patients undergoing total hip or knee arthroplasty, DOACs did not significantly reduce 30-day VTE risk compared to aspirin but were associated with a higher risk of postoperative bleeding.
Simon et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: